Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myelodysplastic syndromes.

A C Yeomans, M T Harle

    Seminars in Oncology Nursing
    |February 1, 1990
    PubMed
    Summary
    This summary is machine-generated.

    Currently, there is no cure for Myelodysplastic Syndromes (MDS). Treatment focuses on supportive care and new therapies like hematopoietic growth factors to manage symptoms and prevent progression to leukemia.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.

    Cancer·2000
    Same author

    Behavioral and social factors that predict participation in the Breast Cancer Prevention Trial.

    Annals of the New York Academy of Sciences·1995
    Same author

    Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1993
    Same author

    Occult primary malignancies.

    Oncology nursing forum·1991
    Same author

    Assessment and management of gouty arthritis.

    The Nurse practitioner·1991
    Same author

    Assessment and management of hypothyroidism.

    The Nurse practitioner·1990

    Area of Science:

    • Hematology
    • Oncology

    Background:

    • Myelodysplastic Syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
    • MDS is characterized by ineffective hematopoiesis and a high risk of transformation to acute myeloid leukemia.
    • Currently, no curative treatment exists for MDS.

    Purpose of the Study:

    • To outline the current therapeutic landscape for Myelodysplastic Syndromes (MDS).
    • To discuss supportive care strategies and emerging treatment modalities.
    • To explore future directions in MDS treatment.

    Main Methods:

    • Review of current clinical practices in MDS management.
    • Evaluation of supportive care interventions, including blood product transfusions and antibiotics.
    • Assessment of hematopoietic growth factors as a therapeutic option.

    Related Experiment Videos

  • Discussion of investigational drugs and combination therapies.

    • Main Results:

    • Supportive care remains the mainstay of MDS treatment.
    • Hematopoietic growth factors show promise in reversing cytopenias.
    • Investigational drugs are frequently offered due to the lack of curative options.

    Conclusions:

    • MDS treatment aims to restore normal hematopoiesis and prevent acute leukemia.
    • Future MDS therapies will likely involve combination treatments, including biological agents, retinoic acid, vitamin D, low-dose Ara-C, interferons, and colony-stimulating factors.